Skip to content
The Nexus
HEALTHJul 30 · 13:08 UTCSTAT NEWSEd Silverman

STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more

An FDA advisory panel rejected a Duchenne muscular dystrophy drug by a 9-to-3 vote due to insufficient effectiveness data, and the FTC sued Hims & Hers over alleged misleading health data practices and subscription billing issues.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
U.S. Food and Drug AdministrationorganizationCapricor TherapeuticsorganizationDuchenne muscular dystrophytopicU.S. Federal Trade CommissionorganizationHims & HersorganizationUtahplaceCaliforniaplace
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting